Idenix Pharmaceuticals Inc. has appointed Ronald C. Renaud, Jr. as president, CEO and board member of the Cambridge biotech, following the resignation of previous president, CEO, chairman and company founder Jean-Pierre Sommadossi.
Renaud’s appointment follows a progression in positions from his first post at Idenix in 2007 as chief financial officer and treasurer and as chief business officer in June of this year. Before joining Idenix, Renaud worked as senior vice president and CFO of Keryx Biopharmaceuticals Inc., a New York-based biotech focused on renal disease and cancer. Previous positions include biotechnology analyst roles at Bearn Stearns, Schwab Soundview and JPMorgan, as well as clinical research, finance and investor relations roles at Amgen. Renaud earned a bachelor’s degree from Saint Anselm College and a MBA from the University of Southern California’s Marshall School of Business.